← All trials
NCT05788497
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- Mar 29, 2023
- Last posted
- Dec 5, 2023
- Enrollment
- 195
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Faes Farma, S.A.Lead sponsor
- Dynamic Science S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.